PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
 
J Clin Microbiol. May 2003; 41(5): 2153–2155.
PMCID: PMC154669
Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Patients with Various Levels of Exposure to Highly Active Antiretroviral Therapy
Robert J. O'Connell,1* Teresa M. Merritt,1 Jennifer A. Malia,2 Thomas C. VanCott,3 Matthew J. Dolan,1 Hassan Zahwa,2 William P. Bradley,3 Bernard M. Branson,4 Nelson L. Michael,2 and Caroline C. De Witt1
Wilford Hall Medical Center, Lackland Air Force Base, Texas 78236,1 Division of Retrovirology, Walter Reed Army Institute for Research,2 Henry M. Jackson Foundation, Rockville, Maryland 20850,3 National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 303334
*Corresponding author. Mailing address: Department of Infectious Diseases, Wilford Hall Medical Center, 59MDW/MMII, 2200 Bergquist Dr., Ste. 1, Lackland AFB, TX 78236. Phone: (210) 292-2225. Fax: (210) 292-3740. E-mail: robert.oconnell/at/lackland.af.mil.
Received July 11, 2002; Revised November 29, 2002; Accepted February 7, 2003.
Abstract
With oral mucosal transudate and serum samples from 101 human immunodeficiency virus type 1 (HIV-1)-infected subjects and 100 HIV-1-negative volunteers, the OraQuick HIV-1 test demonstrated 100% specificity and 96% sensitivity. Four false-negative subjects, who were characterized by early initiation of effective antiretroviral therapy, demonstrated waning serum anti-gp41 titers and Western blot band intensities.
Point-of-care human immunodeficiency virus (HIV) diagnosis has advantages over conventional testing in time-critical settings (1-3, 5, 6, 8, 11, 12). The OraQuick HIV type 1 (HIV-1) rapid antibody test (OraQuick; OraSure Technologies, Bethlehem, Pa.), is designed as a rapid test that uses oral mucosal transudate (OMT), whole blood, serum, or plasma. It was approved by the U.S. Food and Drug Administration in November 2002 for HIV-1 diagnosis by using finger-stick whole blood. OraQuick detects gp41 immunodominant domain antibody. Early trials of OraQuick on OMT, blood, and serum demonstrated 100% sensitivity and 99.8% specificity (B. Branson, M. Uniyal, C. Fridlund, T. Granade, and P. Kerndt, 9th Conf. Retrovir. Opportunistic Infect., abstr. 599-T, 2002; S. Nookai, C. Sinthuwattannawibool, P. Phanuphak, and R. George, 8th Conf. Retrovir. Opportunistic Infect., abstr. 232, 2001).
To evaluate OraQuick with serum and OMT, we studied a cohort of patients whose HIV infection status was known and then expanded the evaluation to characterize the clinical features and antibody response characteristics associated with lower-than-expected OraQuick sensitivity. One hundred volunteers at low risk for HIV infection and 101 HIV-1-infected patients were recruited from an ongoing HIV natural history study. The voluntary, fully informed consent of the subjects used in this research was obtained as required by Air Force Regulation 169-9.
OraQuick testing was performed according to the directions on the package insert. OraQuick test results were read by the study technician and an observer unaware of the patient's HIV status. Serum specimens were subjected to enzyme immunoassay (EIA) (Genetic Systems rLAV; Bio-Rad Laboratories, Redmond, Wash.). Repeatedly reactive specimens were tested by Western blotting (Cambridge Biotech HIV-1 Western blot; Calypte Biomedical Corp., Rockville, Md.). Band reactivity was assigned a value from 0 (no reactivity) to 3 (strongly reactive). Viral load (VL) testing was performed with the Amplicor HIV-1 Monitor test (Roche Molecular Systems, Inc., Branchburg, N.J.) in ultrasensitive mode. Highly active antiretroviral therapy (HAART) was defined as a regimen containing at least three medications, including nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors, in which at least one agent was abacavir, any protease inhibitor, or any nonnucleoside reverse transcriptase inhibitor.
After four HIV-infected subjects tested negative with OraQuick (case subjects), 20 subjects were randomly selected from the 97 HIV-1-infected subjects who tested positive with OraQuick (control subjects). Serum had been collected semiannually from all HIV-infected participants in the natural history study and stored at −20°C. The earliest available archived serum was tested with OraQuick. A gp41 peptide EIA (10) was performed on all specimens.
Statistical analysis was performed with the Statistical Package for the Social Sciences, version 10.0.7 (SPSS Inc., Chicago, Ill.). Continuous variables were analyzed by an independent-sample t test or a Mann-Whitney U test; categorical variables were analyzed by a chi-square test, Fisher's exact test, or Kruskal-Wallis one-way analysis of variance. Interobserver agreement was examined with Cohen's kappa test. Nonnumeric VL values reported as <50 were assigned values of 25, and those reported as >750,000 were assigned values of 750,001. Control subjects were selected by using random numbers generated by Microsoft Excel 97.
OraQuick was reactive with OMT and sera from 97 of 101 HIV-infected subjects and 0 of 100 subjects who were uninfected (sensitivity and specificity, 96 and 100%, respectively). Concordance between serum and OMT testing and interobserver concordance (kappa = 1.0, P < 0.001) were 100%. The mean time since HIV diagnosis for the 101 HIV-infected subjects was 7.0 years, 91 (90%) subjects had ever received HAART, and 80 (79%) subjects were taking HAART on the OraQuick study date.
OraQuick was reactive with archival sera from all four subjects who were HIV negative by OraQuick and from all 20 control subjects. Anti-gp41 was detectable in three of four archival specimens from the OraQuick false-negative subjects but in none of their study date specimens (Table (Table1).1). gp41 antibody was detectable in 19 of 20 control group archival specimens and all 20 study specimens. For the archived specimens, there was no statistically significant difference in anti-gp41 reactivity between the four OraQuick false-negative subjects and the 20 OraQuick-reactive control subjects (P = 0.31). For the study specimens, however, a significantly higher proportion of OraQuick false-negative specimens had undetectable anti-gp41 titers than did the 20 OraQuick-reactive control specimens (P = 0.00047). Both archived and study specimens from all 24 subjects in the case-control study were reactive by HIV-1 EIA and Western blotting.
TABLE 1.
TABLE 1.
Anti-gp41 titers in archived and study specimens from OraQuick-reactive and OraQuick-negative HIV-infected patients
The 20 control subjects and the 77 subjects whose specimens were OraQuick reactive and who were not included in the case-control study did not differ significantly by age, HIV-1 infection time, proportion on HAART, HAART duration, or CD4 count (data not shown). These characteristics were also similar for case and control subjects (Table (Table2).2). However, VL was undetectable (<50 copies/ml) at the time of the study in all four OraQuick false-negative subjects compared with 7 of 20 control subjects (P = 0.034). The OraQuick false-negative subjects had initiated HAART sooner after HIV diagnosis than had the 17 HAART-experienced OraQuick-reactive subjects (0.31 versus 3.52 years, P = 0.025). The OraQuick-negative subjects also had significantly higher HAART ratios (HAART duration divided by known duration of HIV infection) than did the OraQuick-reactive control subjects (0.92 versus 0.45, P = 0.002).
TABLE 2.
TABLE 2.
Characteristics of HIV-infected case subjects whose specimens were OraQuick false negative and control subjects whose specimens were OraQuick reactivea
Western blot band intensity was significantly lower with study sera from the four OraQuick-negative subjects than with those of the 20 OraQuick-reactive control subjects. Furthermore, Western blot band intensity was inversely proportional to effective HAART exposure when the 101 HIV-infected subjects were stratified into four groups with ascending HAART exposure defined as follows: no HAART therapy (“never HAART”), HAART with detectable HIV VL (“HAART+ detectable”), HAART with undetectable HIV VL (“HAART+ undetectable”), and the four OraQuick-negative subjects (OraQuick false negative) (Table (Table3).3). Five of the 51 HAART+ undetectable subjects had HAART ratios that equaled or exceeded the mean HAART ratio for the four OraQuick false-negative subjects.
TABLE 3.
TABLE 3.
Comparison of Western blot band intensities for specimens of HIV-infected subjects, by OraQuick reactivity and exposure to effective HAART
OraQuick contains a synthetic gp41 peptide for HIV antibody detection. While OraQuick performed equally well with OMT and serum, sensitivity was reduced with specimens from some HIV-infected subjects with heavy HAART exposure. Sera and OMT collected for the study from four HIV-infected subjects were not reactive by OraQuick, but archived sera were reactive. All four subjects had undetectable anti-gp41 levels on the date of the nonreactive OraQuick test and viral loads of <50 copies/ml. These data suggest that these subjects experienced anti-gp41 seroreversion as a consequence of early and prolonged suppression of viremia by HAART. Reduction in antibodies to HIV gp120, gp41, and p24 following HAART has been recognized elsewhere (4, 7, 9). Morris and colleagues suggested that reduction in HIV-1-specific antibody levels with HAART is due to a reduction of B-cell hyperresponsiveness (9). Kim and colleagues showed specific reductions in HIV-1-specific antibody responses to the gp41 immunodominant domain in chronically infected patients treated with HAART (7). Antibody levels promptly increase if viral suppression is not maintained (4, 7, 9). The data presented here suggest that diagnostic devices do not always perform comparably in HAART-naïve and HAART-treated individuals.
HAART-treated patients should be included in the evaluation of HIV-1 diagnostic tests. Such patients may present for testing being unable or unwilling to disclose their infection status. Clinical testing in support of Food and Drug Administration submissions for HIV diagnostic device approval must be performed on known HIV-seropositive and HIV-seronegative individuals with a significant proportion of seropositive subjects in resource-rich countries receiving HAART. Present data preclude an estimate of the number of HIV-1-seropositive individuals on HAART who present for testing without revealing their serostatus. HIV diagnostics based solely on gp41 reactivity may fail to detect HIV infection in HAART-treated patients treated early and effectively following diagnosis. OraQuick might optimally be used in parallel with an HIV diagnostic test based on different or multiple epitopes in which discordant test pairs are submitted to confirmatory testing when clinical suspicion of HIV infection is high.
Acknowledgments
We thank Marcin Iwanicki for technical assistance, Sam Niedbala for manuscript review, and Deborah Birx for continued support.
The views expressed here are the private opinions of the authors and are not to be considered as official or reflecting the views of the U.S. Air Force, the U.S. Army, the U.S. Department of Defense, or the U.S. Department of Health and Human Services. Use of trade names is for identification only and does not imply endorsement by the U.S. government.
This work was supported in part by cooperative agreement no. DAMD17-93-V-3004, between the U.S. Army Medical Research and Materiel Command and the Henry M. Jackson Foundation for the Advancement of Military Medicine.
1. Bakari, J. P., S. McKenna, A. Myrick, K. Mwinga, G. J. Bhat, and S. Allen. 2000. Rapid voluntary testing and counseling for HIV. Acceptability and feasibility in Zambian antenatal care clinics. Ann. N. Y. Acad. Sci. 918:64-76. [PubMed]
2. Centers for Disease Control and Prevention. 2001. Routinely recommended HIV testing at an urgent-care clinic, Atlanta, Georgia, 2000. Morb. Mortal. Wkly. Rep. 50:538-541. [PubMed]
3. Centers for Disease Control and Prevention. 1998. Update: HIV counseling and testing using rapid tests—United States, 1995. Morb. Mortal. Wkly. Rep. 47:211-215. [PubMed]
4. Dorn, J., S. Masciotra, C. Yang, R. Downing, B. Biryahwaho, T. D. Mastro, J. Nkengasong, D. Pieniazek, M. A. Rayfield, D. J. Hu, and R. B. Lal. 2000. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection. J. Clin. Microbiol. 38:773-780. [PMC free article] [PubMed]
5. Giles, R. E., K. R. Perry, and J. V. Parry. 1999. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? J. Med. Virol. 59:104-109. [PubMed]
6. Henderson, D. K. 1999. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 281:931-936. [PubMed]
7. Kim, J., J. Mascola, S. Ratto-Kim, T. VanCott, L. Loomis-Price, J. Cox, N. Michael, L. Jagodinski, J. Mansfield, C. Hawkes, D. Mayers, B. Gilliam, D. Birx, and M. Robb. 2001. Selected increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res. Hum. Retrovir. 17:1021-1034. [PubMed]
8. McKenna, S. L., G. K. Muyinda, D. Roth, M. Mwali, N. Ng'andu, A. Myrick, C. Luo, F. H. Priddy, V. M. Hall, A. A. von Lieven, J. R. Sabatino, K. Mark, and S. A. Allen. 1997. Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS 11:S103-S110. [PubMed]
9. Morris, L., J. M. Binley, B. A. Clas, S. Bonhoeffer, T. P. Astill, R. Kost, A. Hurley, Y. Cao, M. Markowitz, D. D. Ho, and J. P. Moore. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188:233-245. [PMC free article] [PubMed]
10. VanCott, T. C., J. R. Mascola, R. W. Kaminski, V. Kalyanaraman, P. L. Hallberg, P. R. Burnett, J. T. Ulrich, D. J. Rechtman, and D. L. Birx. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330. [PMC free article] [PubMed]
11. Wiley, D. J., R. R. Frerichs, W. L. Ford, and P. A. Simon. 1998. Failure to learn human immunodeficiency virus test results in Los Angeles public sexually transmitted disease clinics. Sex. Transm. Dis. 25:342-345. [PubMed]
12. Wilkinson, D., N. Wilkinson, C. Lombard, D. Martin, A. Smith, K. Floyd, and R. Ballard. 1997. On-site HIV testing in resource-poor settings: is one rapid test enough? AIDS 11:377-381. [PubMed]
Articles from Journal of Clinical Microbiology are provided here courtesy of
American Society for Microbiology (ASM)